Serum M-spike and transplant outcome in patients with multiple myeloma

Cancer Science

Volumn 98, Issue 7, 2007, Pages 1035-1040

  Dingli, David ^a,b   Pacheco, Jorge M ^b,c   Dispenzieri, Angela ^a   Hayman, Suzanne R ^a   Kumar, Shaji K ^a   Lacy, Martha Q ^a   Gastineau, Dennis A ^a   Gertz, Morie A ^a  

^a Mayo Clinic   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; M PROTEIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA CELL; MULTIPLE MYELOMA; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; FEMALE; HUMANS; IMMUNOGLOBULINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 34249890023     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00499.x     Document Type: Article

References (44)

1. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822-4.
2. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-7.
3. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-83.
4. Group MTC. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma. An overview of 6633 patients from 27 randomized studies. J Clin Oncol 1998; 16: 3832-42.
5. Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006; 367: 825-31.
6. Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-23.
7. Cunningham D, Paz-Ares L, Milan S et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12: 759-63.
8. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
9. Vesole DH, Tricot G, Jagannath S et al. Autotransplants in multiple myeloma: What have we learned? Blood 1996; 88: 838-47.
10. Alexanian R, Weber D, Giralt S et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037-43.
11. Blade J, Rosinol L, Sureda A et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755-9.
12. Barlogie B, Kyle RA, Anderson KC et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929-36.
13. Fermand JP, Katsahian S, Divine M et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55-65.years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227-33.
14. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-6.
15. Gertz MA, Lacy MQ, Inwards DJ et al. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Bone Marrow Transplant 1999; 23: 221-6.
16. Gertz MA, Lacy MQ, Inwards DJ et al. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant 2000; 26: 45-50.
17. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: 86-9.
18. Durie BG, Kyle RA, Belch A et al. Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4: 379-98.
19. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-6.
20. Ghobrial IM, Dispenzieri A, Bundy KL et al. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant 2003; 32: 587-92.
21. Sullivan PW, Salmon SE. Kinetics of tumor growth and regression in IgG multiple myeloma. J Clin Invest 1972; 51: 1697-708.
22. Durie BG, Salmon SE. Cellular kinetics staging, and immunoglobulin synthesis in multiple myeloma. Annu Rev Med 1975; 26: 283-8.
23. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-20.
24. Bataille R, Durie BG, Grenier J. Serum beta2 microglobulin and survival duration in multiple myeloma: A simple reliable marker for staging. Br J Haematol 1983; 55: 439-47.
25. Cuzick J, De Stavola BL, Cooper EH, Chapman C, MacLennan IC. Long-term prognostic value of serum beta 2 microglobulin in myelomatosis. Br J Haematol 1990; 75: 506-10.
26. Blade J, Rozman C, Cervantes F, Reverter JC, Montserrat E. A new prognostic system for multiple myeloma based on easily available parameters. Br J Haematol 1989; 72: 507-11.
27. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-23.
28. Buffaloe GW, Heineken FG. Plasma volume nomograms for use in therapeutic plasma exchange. Transfusion 1983; 23: 355-7.
29. Salmon SE, Durie BG. Cellular kinetics in multiple myeloma. A new approach to staging and treatment. Arch Intern Med 1975; 135: 131-8.
30. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23: 6333-8.
31. Durie BG, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in Southwest Oncology Group chemotherapy trials. J Clin Oncol 2004; 22: 1857-63.
32. Porrata LF, Adjei AA. The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours. Br J Cancer 2001; 85: 484-9.
33. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-502.
34. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. BLOOD 1997; 89: 789-93.
35. Rajkumar SV, Fonseca R, Lacy MQ et al. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant 1999; 23: 1261-6.
36. Rajkumar SV, Fonseca R, Dispenzieri A et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000; 26: 979-83.
37. Nadal E, Gine E, Blade J et al. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant 2004; 33: 61-4.
38. West GB, Savage VM, Gillooly J, Enquist BJ, Woodruff WH, Brown JH. Physiology: Why does metabolic rate scale with body size? Nature 2003; 421: 713; discussion 714.
39. Messmer BT, Messmer D, Allen SL et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115: 755-64.
40. Kozusko F, Bajzer Z. Combining Gompertzian growth and cell population dynamics. Math Biosci 2003; 185: 153-67.
41. Bajzer Z. Gompertzian growth as a self-similar and allometric process. Growth Dev Aging 1999; 63: 3-11.
42. West GB, Brown JH, Enquist BJ. A general model for ontogenetic growth. Nature 2001; 413: 628-31.
43. Tabrizi MA, Tseng C-M, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006; 11: 81-8.
44. Cunningham D, Powles R, Malpas J et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: Long-term follow-up results. Br J Haematol 1998; 102: 495-502.